Abstract:Continuous cell culture-based influenza vaccine production could significantly reduce footprint and manufacturing costs compared to current batch processing. However, yields of influenza virus in continuous mode can be affected by oscillations in virus titers caused by periodic accumulation of defective interfering particles. The generation of such particles has also been observed previously in cascades of continuous stirred tank reactors (CSTRs) and is known as the "von Magnus effect". To improve virus yields and to avoid these oscillations, we have developed a novel continuous tubular bioreactor system for influenza A virus production. It was built using a 500 mL CSTR for cell growth linked to a 105 m long tubular plug-flow bioreactor (PFBR). Virus propagation took place only in the PFBR with a nominal residence time of 20 h and a production capacity of 0.2 mL/min. The bioreactor was first tested with suspension MDCK cells at different multiplicities of infection (MOI), and then with suspension avian AGE1.CR.pIX cells at a fixed nominal MOI of 0.02. Maximum hemagglutinin (HA) titers of 2.4 and 1.6 log10(HA units/100 μL) for suspension MDCK cells and AGE1.CR.pIX cells, respectively, were obtained. Flow cytometric analysis demonstrated that 100% infected cells with batch-like HA titers can be obtained at a MOI of at least 0.1. Stable HA and TCID50 titers over 18 days of production were confirmed using the AGE1.CR.pIX cell line, and PCR analysis demonstrated stable production of full-length genome. The contamination level of segments with deletions (potentially defective interfering particles), already present in the virus seed, was low and did not increase. Control experiments using batch and semi-continuous cultures confirmed these findings. A comparison showed that influenza virus production can be achieved with the tubular bioreactor system in about half the time with a space-time-yield up to two times higher than for typical batch cultures. In summary, a novel continuous tubular bioreactor system for cell culture-based influenza virus production was developed. One main advantage, an essentially single-passage amplification of viruses, should enable efficient production of vaccines as well as vectors for gene and cancer therapy.

Continuous Manufacturing of Lentiviral Vectors using a Stable Producer Cell Line in a Fixed-Bed Bioreactor

Quasi-perfusion studies for intensified lentiviral vector production using a continuous stable producer cell line

Development of a perfusion process for continuous lentivirus production using stable suspension producer cell lines

Production of Lentiviral Vectors Using a HEK-293 Producer Cell Line and Advanced Perfusion Processing

Optimization of lentiviral vector production for scale-up in fixed-bed bioreactor

Optimised protocols to generate high titre lentiviral vectors using a novel transfection agent enabling extended HEK293T culture following transient transfection and suspension culture

A Scalable Lentiviral Vector Production and Purification Method Using Mustang Q Chromatography and Tangential Flow Filtration

Establishment and Characterization of a Stable Producer Cell Line Generation Platform for the Manufacturing of Clinical-Grade Lentiviral Vectors

Lentiviral vector packaging and producer cell lines yield titers equivalent to the industry-standard four-plasmid process

Phase I/II Manufacture of Lentiviral Vectors Under GMP in an Academic Setting

Exploring nutrient supplementation and bioprocess optimization to improve the production of lentiviral vectors in serum‐free medium suspension cultures

Perfusion Process Intensification for Lentivirus Production Using a Novel Scale‐Down Model

High yield sterile filtration process for highly concentrated lentiviral vectors

Continuous influenza virus production in a tubular bioreactor system provides stable titers and avoids the "von Magnus effect"

Process Optimization for the Rapid Production of Adenoviral Vectors for Clinical Trials in a Disposable Bioreactor System.

Development of Novel Lipoplex Formulation Methodologies to Improve Large Scale Transient Transfection for Lentiviral Vector Manufacture

Generation of a stable packaging cell line producing high-titer PPT-deleted integration-deficient lentiviral vectors

Advances in Lentivirus Purification

Comprehensive Untargeted Lipidomic Profiling of Third Generation Lentiviral Vectors and Packaging Cells

Lentiviral vectors with two independent internal promoters transfer high-level expression of multiple transgenes to human hematopoietic stem-progenitor cells.

Establishing functional lentiviral vector production in a stirred bioreactor for CAR-T cell therapy